Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)
批准号:
10472728
负责人:
Steven M Kawut
金额:
$110.65万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-20 至 2026-05-31
关键词:
AccelerometerAddressAdultAgeAncillary StudyBiosensorBlood VesselsCardiacCardiopulmonaryCaringCessation of lifeChildhoodClinicalClinical TrialsClinical assessmentsDataDefectDiseaseEducational StatusEmergency department visitEndotheliumEnrollmentEnvironmental Risk FactorEpoprostenolExerciseFrequenciesHospitalizationHourIndividualIntravenousLeadLifeLungLung TransplantationMeasuresMedicalMonitorMuscleObservational StudyOutcome StudyOutpatientsPatient MonitoringPatientsPatternPeripheralPersonal SatisfactionPersonsPhenotypePhysical activityPilot ProjectsPopulationPrincipal Component AnalysisPublishingPulmonary HypertensionPumpQuality of lifeRandomized Clinical TrialsRegistriesSF-12SeveritiesSmooth Muscle MyocytesSymptomsSystemic diseaseTestingTimeUnited StatesWalkingadverse event riskclinical carecohortdata streamsdesignemotional factorevidence baseexercise capacityexercise interventionfitnessfollow-uphealth related quality of lifehigh riskimprovedindexinginnovationinsightinstrumentnovelnovel therapeuticspatient orientedpatient registryphysical modelprospectivepsychosocialpulmonary arterial hypertensionresidenceright ventricular failuresedentarysexside effectsocioeconomicssupplemental oxygentreatment effectvascular bedwearable sensor technology
中文摘要
肺动脉高压(PAH)的特征是即使在电流条件下,
效果治疗。大多数观察性研究、临床试验和门诊患者的临床评估
PAH关注运动能力(一个人在受控环境下可以达到的最大努力),
通过心肺运动或六分钟步行测试来测量。然而,这些人工测试并不
捕捉一天或一周内身体活动的强度、频率、持续时间、背景和模式
在病人的生活中。这样的活动“特征”或表型可以更准确地反映个体的活动。
功能和感知的健康相关生活质量(HRQOL),通过提供对多系统功能的洞察,
副作用和治疗益处及负担。一种身体活动干预,
PAH患者可导致心理社会功能、症状、HRQOL、健身,甚至
生存不幸的是,关于PAH患者体力活动的已发表研究很少,
在一个大型多中心队列中评估了多维度。我们进行了初步研究
使用传统的加速度测量法,该方法显示PAH患者分为低、中和高
活动表型显示六分钟步行距离和HRQOL的差异。功能原理
成分分析已经确定了PAH患者全天身体活动模式的“特征”。小说
在真实的时间内连续捕获多个数据流(包括加速度计)的生物传感器将
为远程临床监测提供了一种创新的方法,
PAH的临床试验。
肺动脉高压协会登记处(PHAR)一直在前瞻性地收集来自
自2015年以来,来自美国各中心的成人和儿童PAH患者。PHAR已经
在52个中心招募了1400名患者,随访2000患者年,代表了最大的
PAH患者的多中心登记研究。我们建议测量一周的加速度
在PHAR中,每两年对> 1400名患者进行一次为期4年的评估(约7000次评估),具有高效率和低成本
患者负担我们的目的是确定体力活动表型的预测因素,以及体力活动是否
模式与健康相关的生活质量,急诊室就诊,住院,
PAH患者至肺移植或死亡的时间。我们将估计物理上的“最小重要差异”,
活性,可用作PAH临床试验的终点。我们会在一个新的可穿戴设备上
生物传感器,可用于推进这些模型的物理活动在PAH。
英文摘要
Pulmonary arterial hypertension (PAH) is characterized by limitation of physical activity even with current
effect treatments. Most observational studies, clinical trials, and outpatient clinical assessments of patients with
PAH focus on exercise capacity (the maximal effort a person can achieve under controlled circumstances),
measured by cardiopulmonary exercise or six minute walk testing. However, these artificial tests do not
capture the intensity, frequency, duration, context, and pattern of physical activity throughout the day or week
in the patient’s life. Such an activity “signature” or phenotype may more accurately reflect an individual’s
function and perceived health-related quality of life (HRQOL) by providing insight into multisystem function,
side effects, and treatment benefits and burdens. A physical activity intervention which is personalized for a
PAH patient could lead to improvements in psychosocial function, symptoms, HRQOL, fitness, and even
survival. Unfortunately, there have been very few published studies of physical activity in PAH patients, none of
which have assessed multidimensionality in a large multicenter cohort. We have performed preliminary studies
using traditional accelerometry which have shown that patients with PAH cluster into low, medium, and high
activity phenotypes which show differences in six minute walk distance and HRQOL. Functional principal
components analysis has identified “signatures” of physical activity patterns throughout the day in PAH. Novel
biosensors which continuously capture multiple streams of data in real time (including accelerometry) would
provide an innovative approach to remote clinical monitoring and may increase the efficiency and pertinence of
clinical trials in PAH.
The Pulmonary Hypertension Association Registry (PHAR) has been prospectively collecting data from
adult and pediatric PAH patients from centers throughout the United States since 2015. The PHAR has
enrolled 1400 patients with 2000 patient-years of follow-up at 52 centers, representing one of the largest
multicenter registries of patients with PAH. We propose to measure accelerometry for one week periods
biannually for > 1400 patients over four years (~7000 assessments) in the PHAR with high efficiency and low
patient burden. We aim to determine the predictors of physical activity phenotype and whether physical activity
patterns are associated with health-related quality of life, emergency department visits, hospitalizations, and
time to lung transplantation or death in PAH. We will estimate the “minimally important difference” in physical
activity which could be used as an end point in clinical trials in PAH. We will incorporate a novel wearable
biosensor which could be used to advance these models of physical activity in PAH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)
-
批准号:10317293
-
项目类别:
-
资助金额:$112.35万
-
财政年份:2021
-
负责人:Steven M Kawut
-
依托单位:
Physical Activity in Pulmonary Arterial Hypertension (ACTiPH)
-
批准号:10686332
-
项目类别:
-
资助金额:$116.12万
-
财政年份:2021
-
负责人:Steven M Kawut
-
依托单位:
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
-
批准号:10470370
-
项目类别:
-
资助金额:$73.58万
-
财政年份:2021
-
负责人:Steven M Kawut
-
依托单位:
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
-
批准号:10312558
-
项目类别:
-
资助金额:$85.12万
-
财政年份:2021
-
负责人:Steven M Kawut
-
依托单位:
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
-
批准号:10683186
-
项目类别:
-
资助金额:$69.28万
-
财政年份:2021
-
负责人:Steven M Kawut
-
依托单位:
Novel Mechanisms of Hepatopulmonary Syndrome
-
批准号:10166906
-
项目类别:
-
资助金额:$76.95万
-
财政年份:2018
-
负责人:Steven M Kawut
-
依托单位:
Novel Mechanisms of Hepatopulmonary Syndrome
-
批准号:10434096
-
项目类别:
-
资助金额:$79.76万
-
财政年份:2018
-
负责人:Steven M Kawut
-
依托单位:
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
-
批准号:8499401
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
-
批准号:8662302
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
-
批准号:8843525
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension
-
批准号:9764412
-
项目类别:
-
资助金额:$11.94万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
-
批准号:8258295
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Mentored Patient-Oriented Research in Pulmonary Arterial Hypertension
-
批准号:9162832
-
项目类别:
-
资助金额:$11.94万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
-
批准号:8112879
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2011
-
负责人:Steven M Kawut
-
依托单位:
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
-
批准号:7842027
-
项目类别:
-
资助金额:$16.34万
-
财政年份:2009
-
负责人:Steven M Kawut
-
依托单位:
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis
-
批准号:7544910
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2007
-
负责人:Steven M Kawut
-
依托单位:
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis
-
批准号:7335629
-
项目类别:
-
资助金额:$59.8万
-
财政年份:2007
-
负责人:Steven M Kawut
-
依托单位:
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis
-
批准号:7184735
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2007
-
负责人:Steven M Kawut
-
依托单位:
Endothelial Dysfunction and the RV in the Multi-Ethnic Study of Atherosclerosis
-
批准号:7809481
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2007
-
负责人:Steven M Kawut
-
依托单位:
A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
-
批准号:7185839
-
项目类别:
-
资助金额:$60.43万
-
财政年份:2006
-
负责人:Steven M Kawut
-
依托单位:
海外基金